PMID: 6170414Nov 15, 1981Paper

Treatment of acute nonlymphocytic leukemia in adults: response to 2,2-anhydro-1-B-D-arabinofuranosyl-5-fluorocytosine and thioguanine on the L-12 protocol

Cancer
R MertelsmannB D Clarkson

Abstract

Fifty-one adult patients with acute nonlymphocytic leukemia (excluding acute promyelocytic leukemia) were treated on the L-12 protocol. The L-12 differed from the preceding L-6 in that 2,2-anhydro-1-B-D-arabinofuranosyl-5-fluorocytosine (AAFC), replaced arabinosylcytosine (ara-C) together with 6-thioguanine (TG) for remission induction. Achievement of remission was followed by an extended 14-week multi-drug consolidation program. With this more intense regimen, an overall complete remission rate of 49% and a median remission duration of 23.7 months were achieved; these results were not significantly better than the 57% complete remission rate and 8.6 months median remission duration obtained with the L-6 regimen. Four year disease-free survival was 22% on the L-12 compared with 16% on the L-6 protocol. No relationship between prognosis and FAB classification was found on either the L-6 or the L-12 protocol.

References

Dec 28, 1977·European Journal of Clinical Pharmacology·J W AyresJ G Wagner
Jun 1, 1978·Cancer·R L DrapkinB Clarkson
Aug 1, 1978·Cancer·E J FreireichT Smith
May 24, 1979·The New England Journal of Medicine·R P Gale
Sep 13, 1979·The New England Journal of Medicine·E D ThomasP L Weiden
Aug 1, 1975·Cancer·B D ClarksonJ H Burchenal
Jan 1, 1973·Metabolism: Clinical and Experimental·S M KraneJ T Potts
Aug 28, 1980·The New England Journal of Medicine·H J WeinsteinE Frei

❮ Previous
Next ❯

Citations

Nov 20, 2002·The Journal of Clinical Investigation·Wolfgang E GallwitzGregory R Mundy
Jul 1, 1985·Cancer·K KawashimaN Hamajima

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.